Abstract

PurposePathological studies suggest that neuroinflammation is exacerbated by increased beta-amyloid (Aβ) levels in the brain early in Alzheimer’s disease (AD). The time course and relationships between astrocytosis and Aβ deposition were examined using multitracer in vivo positron emission tomography (PET) imaging in an AD transgenic mouse model, followed by postmortem autoradiography and immunohistochemistry analysis.MethodsPET imaging with the amyloid plaque tracer 11C-AZD2184 and the astroglial tracer 11C-deuterium-L-deprenyl (11C-DED) was carried out in APPswe mice aged 6, 8–15 and 18–24 months (4–6 animals/group) and in wild-type (wt) mice aged 8–15 and 18–24 months (3–6 animals/group). Tracer uptake was quantified by region of interest analysis using PMOD software and a 3-D digital mouse brain atlas. Postmortem brain tissues from the same APPswe and wt mice in all age groups were analysed for Aβ deposition and astrocytosis by in vitro autoradiography using 3H-AZD2184, 3H-Pittsburgh compound B (PIB) and 3H-L-deprenyl and immunostaining performed with antibodies for Aβ42 and glial fibrillary acidic protein (GFAP) in sagittal brain sections.Results11C-AZD2184 PET retention in the cerebral cortices of APPswe mice was significantly higher at 18–24 months than in age-matched wt mice. Cortical and hippocampal 11C-DED PET binding was significantly higher at 6 months than at 8–15 months or 18–24 months in APPswe mice, and it was also higher than at 8–15 months in wt mice. In vitro autoradiography 3H-AZD2184 and 3H-PIB binding confirmed the in vivo findings with 11C-AZD2184 and demonstrated age-dependent increases in Aβ deposition in APPswe cortex and hippocampus. There were no significant differences between APPswe and wt mice in 3H-L-deprenyl autoradiography binding across age groups. Immunohistochemical quantification demonstrated more Aβ42 deposits in the cortex and hippocampus and more GFAP+ reactive astrocytes in the hippocampus at 18–24 months than at 6 months in APPswe mice.ConclusionThe findings provide further in vivo evidence that astrocytosis occurs early in AD, preceding Aβ plaque deposition.Electronic supplementary materialThe online version of this article (doi:10.1007/s00259-015-3047-0) contains supplementary material, which is available to authorized users.

Highlights

  • Alzheimer’s disease (AD) is the most common neurodegenerative disease and dementia disorder

  • We recently reported that florbetaben, Pittsburgh compound B (PIB) and florbetapir all bind to a high-affinity binding site in postmortem AD brain tissues [12], demonstrating their reliability for detecting fibrillar Aβ deposits

  • We investigated the time course of astrocytosis and amyloid plaque deposition by multitracer in vivo microPET imaging in APPswe mice aged 6–24 months

Read more

Summary

Introduction

Alzheimer’s disease (AD) is the most common neurodegenerative disease and dementia disorder. Recent advancements in molecular imaging using positron emission tomography (PET) have allowed the visualization of fibrillar Aβ plaques and the monitoring of disease progression in vivo in AD patients [3]. Amyloid tracers developed for human use include 11C-Pittsburgh compound B (11C-PIB) [4], 11C-BF-227 [5], 11C-AZD2184 [6], 18F-FDDNP [7], 18F-florbetapir [8], 18Fflutemetamol [9], 18F-florbetaben [10] and 18F-AZD4694 [11]. We recently reported that florbetaben, PIB and florbetapir all bind to a high-affinity binding site in postmortem AD brain tissues [12], demonstrating their reliability for detecting fibrillar Aβ deposits. Longitudinal amyloid PET imaging in large at-risk and patient populations has shown that it takes≈20 years for build-up of pathological amyloid plaque load in the brain [13]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.